The role of JAK2 inhibitors in MPNs 7 years after approval

This article takes a look back at the progress of JAK2 inhibitors in the treatment of MPNs since their approval 7 years ago and discusses the current unmet needs, including defining ruxolitinib failure and designing new trials.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.